Adcetris and Breastfeeding

Because of the unknown risks of breastfeeding while using Adcetris (brentuximab vedotin), the manufacturer of the drug recommends that women not use it while nursing. Although no research has been done on whether the drug passes through breast milk, Adcetris is associated with potentially serious side effects, and the potential dangers to a nursing infant cannot yet be ruled out.

Can Breastfeeding Women Receive Adcetris?

Adcetris™ (brentuximab vedotin) is a prescription medication used in the treatment of certain types of lymphoma, including Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, a rare type of non-Hodgkin's lymphoma. It is unknown if the medication passes through breast milk. The manufacturer of the drug recommends that breastfeeding women should either stop breastfeeding or stop using Adcetris.

More Information About Adcetris and Breastfeeding

Adcetris has not been studied in breastfeeding women. Therefore, it is unknown whether the medicine passes through breast milk, or if it would harm a nursing child.

Adcetris is associated with potentially serious side effects, including low white blood cell counts that can increase the risk for infections. Until more information is known about Adcetris and breastfeeding, the risk for side effects in a nursing infant cannot be ruled out. Therefore, it may be best to avoid nursing during treatment with this chemotherapy drug.

Talking With Your Healthcare Provider

You should discuss breastfeeding and Adcetris use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.